KR100526696B1 - 1,4-디아제판-2,5-디온 유도체 및 ｎｋ-1 수용체길항제로서의 이들의 용도 - Google Patents

1,4-디아제판-2,5-디온 유도체 및 ｎｋ-1 수용체길항제로서의 이들의 용도 Download PDF

Info

Publication number
KR100526696B1
KR100526696B1 KR10-2002-7015837A KR20027015837A KR100526696B1 KR 100526696 B1 KR100526696 B1 KR 100526696B1 KR 20027015837 A KR20027015837 A KR 20027015837A KR 100526696 B1 KR100526696 B1 KR 100526696B1
Authority
KR
South Korea
Prior art keywords
formula
benzyl
compound
dichloro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2002-7015837A
Other languages
English (en)
Korean (ko)
Other versions
KR20030003759A (ko
Inventor
갈레이구이도
고델티에리
괴르글러아니크
헥라인하르트
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20030003759A publication Critical patent/KR20030003759A/ko
Application granted granted Critical
Publication of KR100526696B1 publication Critical patent/KR100526696B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2002-7015837A 2000-05-25 2001-05-18 1,4-디아제판-2,5-디온 유도체 및 ｎｋ-1 수용체길항제로서의 이들의 용도 Expired - Fee Related KR100526696B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00111249 2000-05-25
EP00111249.9 2000-05-25
PCT/EP2001/005723 WO2001090083A1 (en) 2000-05-25 2001-05-18 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists

Publications (2)

Publication Number Publication Date
KR20030003759A KR20030003759A (ko) 2003-01-10
KR100526696B1 true KR100526696B1 (ko) 2005-11-08

Family

ID=8168838

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2002-7015837A Expired - Fee Related KR100526696B1 (ko) 2000-05-25 2001-05-18 1,4-디아제판-2,5-디온 유도체 및 ｎｋ-1 수용체길항제로서의 이들의 용도

Country Status (18)

Country Link
US (1) US6452001B2 (enExample)
EP (1) EP1296961B1 (enExample)
JP (1) JP4060596B2 (enExample)
KR (1) KR100526696B1 (enExample)
CN (1) CN1178923C (enExample)
AR (1) AR028607A1 (enExample)
AT (1) ATE353881T1 (enExample)
AU (2) AU2001281778B2 (enExample)
BR (1) BR0111062A (enExample)
CA (1) CA2409842C (enExample)
DE (1) DE60126614T2 (enExample)
DK (1) DK1296961T3 (enExample)
ES (1) ES2280392T3 (enExample)
MX (1) MXPA02011464A (enExample)
PE (1) PE20011266A1 (enExample)
PT (1) PT1296961E (enExample)
WO (1) WO2001090083A1 (enExample)
ZA (1) ZA200208940B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
DE602006016168D1 (de) * 2005-12-29 2010-09-23 Immupharma France Sa 1,3,5-triazepin-dionen zur Behandlung von Malaria
US7777030B2 (en) 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
AU2006331357B2 (en) * 2005-12-29 2012-05-17 Immupharma France Sa Compositions and methods for synthesizing novel heterocyclic therapeutics
JP2009522236A (ja) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー マラリアまたはエイズの処置のためのアザ複素環化合物
AU2006331355B2 (en) * 2005-12-29 2011-09-29 Immupharma France Sa Compositions and methods for the inhibition of phospholipase A2
WO2007139992A2 (en) * 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
KR101044833B1 (ko) * 2010-02-10 2011-06-28 (주)혜성나노텍 무차광 온실 보온커텐 종형 개폐장치
CN103951624B (zh) * 2010-08-26 2019-04-16 兴和株式会社 1,4-二氮杂环庚烷衍生物或其盐的制造方法
CA2839385C (en) 2011-06-24 2018-10-30 Construction Research & Technology Gmbh Cementitious composition and admixture
CN108358893A (zh) * 2018-02-10 2018-08-03 安徽唯诗杨信息科技有限公司 一种一锅法合成四氢化苯并-[1,4]-二氮杂环庚烷衍生物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022765A (en) 1975-01-06 1977-05-10 E. R. Squibb & Sons, Inc. Triazolo[4,3-d][1,4]benzodiazepine-6-ones
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
DE60126614D1 (de) 2007-03-29
ZA200208940B (en) 2004-02-04
AR028607A1 (es) 2003-05-14
BR0111062A (pt) 2003-06-10
KR20030003759A (ko) 2003-01-10
JP2003534332A (ja) 2003-11-18
DE60126614T2 (de) 2007-11-22
CA2409842A1 (en) 2001-11-29
DK1296961T3 (da) 2007-06-04
ES2280392T3 (es) 2007-09-16
EP1296961A1 (en) 2003-04-02
JP4060596B2 (ja) 2008-03-12
MXPA02011464A (es) 2003-04-25
US6452001B2 (en) 2002-09-17
ATE353881T1 (de) 2007-03-15
AU8177801A (en) 2001-12-03
PT1296961E (pt) 2007-05-31
CN1430611A (zh) 2003-07-16
EP1296961B1 (en) 2007-02-14
CA2409842C (en) 2008-07-29
WO2001090083A1 (en) 2001-11-29
CN1178923C (zh) 2004-12-08
US20020010174A1 (en) 2002-01-24
PE20011266A1 (es) 2001-12-14
AU2001281778B2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
RU2351588C2 (ru) Производные n-фенил(пиперидин-2-ил)метил-бензамида и их применение в терапии
CA2175502C (en) Cyclic amide derivatives
TWI299730B (en) Piperidine derivatives,processes for their preparation ,pharmaceutical composition containing them and their medical use
JP5914642B2 (ja) ピラゾール誘導体
JP2002504929A (ja) アロイルピペラジン誘導体、その製造法およびタキキニン拮抗剤としてのその利用
KR20020038800A (ko) 화학적 화합물
JPH10511687A (ja) グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
JPH08333363A (ja) インドール誘導体
KR20010102347A (ko) 3-페닐피리딘 유도체 및 그의 뉴로키닌-1 수용체길항제로서의 용도
JPH08508738A (ja) ５−ｈｔ１ａ及び／又は５−ｈｔ２リガンドとしてのインドール誘導体
JP2001521523A (ja) 化学的シナプス伝達の制御において有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
JP2004500355A (ja) ニューロンの生長及び伸長を刺激する化合物、組成物及び方法
KR20030003759A (ko) 1,4-디아제판-2,5-디온 유도체 및 ｎｋ-1 수용체길항제로서의 이들의 용도
JP2001151754A (ja) ２−（３，５−ビス−トリフルオロメチル−フェニル）−Ｎ−メチル−Ｎ−（６−モルホリン−４−イル−４−ｏ−トリル−ピリジン−３−イル）−イソブチルアミド
US5932593A (en) Piperidine derivatives and anti-platelet agents containing the same
JPH08504786A (ja) ５−ｈｔ▲下１▼様アゴニスト用トリプタミンアナログ
AU2001281778A1 (en) 1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists
AU2005205183B2 (en) Indolylmaleimide derivatives as PKC inhibitors
JPH09500124A (ja) ５‐ｈｔ１ａ受容体拮抗物質としてのｎ‐（ピペリジニル‐１‐アルキル）‐置換シクロヘキサンカルボン酸アミド
JP2007297366A (ja) Ｔ型カルシウムチャネルに拮抗活性を有する新規１，３−ジオキソイソインドール
DE69526509T2 (de) Von indol abgeleitete aromatische ether als "5ht1-like" liganden
NZ253823A (en) Nicotinic acid esters; compounds, preparation and pharmaceutical compositions; intermediate therefor
JPH09512025A (ja) ５ｈｔ▲下２ｃ▼および５ｈｔ▲下２ｂ▼アンタゴニストとしての三環式誘導体
JPS6157582A (ja) 新規なベンゾジアゼピン類
JP3007675B2 (ja) 新規なインドール誘導体

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20090930

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20101101

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20101101

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000